| Report period | 2018 | 2019 | 2020 | 2021 | 2022 | Q1 23 |
|---|---|---|---|---|---|---|
| End date of the reporting period | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Capitalization, $ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Capitalization, $ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Enterprise Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Shareholders Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Current liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Noncurrent liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Total liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Cash and cash equivalents | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Net debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Assets | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Total ordinary shares | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Ordinary share price | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Report period | 2018 | 2019 | 2020 | 2021 | 2022 | Q1 23 TTM |
|---|---|---|---|---|---|---|
| End date of the reporting period | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Sales | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Gross profit | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Operation Income | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Earnings | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Shareholders earnings | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Adjusted Earnings | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Funds From Operations | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Adjusted FFO | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Distributable Cash Flow | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Adjusted DCF | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| EBITDA | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Adjusted EBITDA | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Operation Cashflow | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Capital expenditure | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Free Cash Flow | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| EPS | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
| Ticker | Name | Type | Nominal value | ISIN | Price |
|---|---|---|---|---|---|
| MDGL:US | Madrigal Pharmaceuticals, Inc. | Common share | - | US5588681057 | $215.6 |
ir.madrigalpharma.com
ir.madrigalpharma.com
ir.madrigalpharma.com
ir.madrigalpharma.com| Company name | Madrigal Pharmaceuticals |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 404-380-9263 |
| Mailing address | 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 |
| Website | www.madrigalpharma.com |